MARKSANS PHARMA LTD. - 524404 - Notice Of 31St Annual General Meeting
31st AGM is scheduled to be held on Monday, 28th August, 2023 through VC/OAVM facility08-08-2023
08-08-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Completion of US FDA Post-marketing Adverse Drug Experience (PADE) inspection07-08-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of conference call for analysts and investors on Wednesday, August 16, 2023 at 05:00 p.m.04-08-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation of Newspaper Publication made pursuant to AGM Notice02-08-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Notice to Shareholders regarding transfer of unclaimed dividend and equity shares of the Company to the Investor Education and Protection Fund (IEPF)02-08-2023
MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results Of The Company (Both Standalone And Consolidated) Along With Limited Review Report Thereon For The Quarter Ended 30Th June, 2023
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 ,inter alia, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) along with Limited Review Report thereon for the Quarter ended 30th June, 202302-08-2023
MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (LODR) Regulations, 201527-07-2023
MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for quarter ended June 30, 202314-07-2023
Marksans Pharma shares rally 9% on FDA nod to pain relief tablet
Marksans Pharma's new tablets are similar to Advil Dual Action which is manufactured by GlaxoSmithKline Consumer Healthcare, a London-based company.12-07-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release dated 12th July, 202312-07-2023